CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 145 enrolled
Drug / intervention
18F-MK-6240 +1 moredrug
Likely dose
18F-Florbetaben 10 mLfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03706261
NCT03706261Phase 1Completed
CompareCT.gov

Alzheimer's PET Imaging in Racially/Ethnically Diverse Adults

Adam Brickman·interventional·Posted Oct 15, 2018·Updated Aug 1, 2025

In Brief

A Phase 1 clinical trial evaluating 18F-MK-6240 and 18F-Florbetaben for Alzheimer Disease. Completed, enrolled 145 participants across 1 site.

Detailed Summary

The study employs tau positron emission tomography (PET) imaging in a well-characterized multi-racial/ethnic cohort to examine the extent to which tau pathology is associated with cognition, differences in tau pathology across racial/ethnic groups, and the relationship between MRI markers of small-vessel cerebrovascular disease and tau pathology. The study also investigates amyloid-dependent tau spreading.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlzheimer Disease
CountriesUnited States
CollaboratorsNational Institute on Aging (NIA)

Timeline

Phase 1CompletedFinished
20192020202120222023202420252026
First PostedOct 15, 2018
Enrollment StartMar 22, 2019
Primary CompletionJul 14, 2023
TodayJul 2, 2026
Enrollment to primary: 4.3 yearsPosted 7.7 years ago

Interventions

18F-MK-6240drug

Administration of 5 mCi of 18F-MK-6240 for tau PET.

18F-Florbetabendrug

Administration of 8.1 mCi as a slow single intravenous bolus (6 sec/mL) in a total volume of up to 10 mL of 18F-Florbetaben for Aβ PET imaging.